Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort studyDaniel K. Nomah, Bibiana Morell, Emili Letang et al.|The Lancet HIV|2021Cited by 110
Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohortJosep M. Llibre, Alexandra Montoliu, JM Miró et al.|HIV Medicine|2019Cited by 38
Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping reviewJorge Palacio‐Vieira, Eva González‐Roca, Juliana Reyes‐Urueña et al.|BMC Public Health|2021Cited by 37
Mortality and immunovirological outcomes in patients with advanced HIV disease on their first antiretroviral treatment: differential impact of antiretroviral regimensJoaquín Burgos, Jorge Palacio, Sergio Moreno‐Fornés et al.|Journal of Antimicrobial Chemotherapy|2022Cited by 22
Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched studyDaniel K. Nomah, Maribel Tamayo, Juliana Reyes‐Urueña et al.|Journal of Antimicrobial Chemotherapy|2022Cited by 20